SCHEMBL4044499

SCHEMBL4044499

O=C(NC1CCCCC1)[C@@H](C1CCCCC1)C1(c2cc(Cl)ccc2F)Nc2ccccc2N1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
NR1H4 Q96RI1 3/20 0.41
CYP3A4 P08684 2/20 0.41
KCNH2 Q12809 2/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
RAB9A P51151 6/20 0.41
NPC1 O15118 5/20 0.41
KMT2A Q03164 4/20 0.41
MDM2 Q00987 2/20 0.41
MEN1 O00255 3/20 0.40
EPHX2 P34913 2/20 0.40
LMNA P02545 1/20 0.40
EPHX1 P07099 1/20 0.40
TSHR P16473 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
METAP2 P50579 2/20 0.39
METAP1 P53582 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039445 1.00 CNR1 (0.42) CNR1CNR2NR1H4CYP3A4KCNH2
SCHEMBL4034460 0.92 RAB9A (0.43) CNR1CNR2NR1H4RAB9ANPC1
SCHEMBL4041108 0.90 NPC1 (0.46) RAB9ANPC1KMT2AMEN1EPHX2
SCHEMBL4037704 0.90 TSHR (0.41) NR1H4CYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL4039455 0.88 KMT2A (0.48) CYP3A4CYP2C9RAB9ANPC1KMT2A
SCHEMBL4044809 0.87 NPC1 (0.46) CNR1CNR2NR1H4CYP3A4KCNH2
SCHEMBL4041113 0.86 NPC1 (0.40) CNR1CNR2NR1H4CYP3A4KCNH2
SCHEMBL4044511 0.85 EPHX2 (0.47) RAB9ANPC1KMT2AMEN1EPHX2
SCHEMBL4042732 0.84 NR1H4 (0.44) NR1H4CYP3A4KCNH2CYP2D6CYP2C9
SCHEMBL4039101 0.84 NR1H4 (0.44) NR1H4CYP3A4KCNH2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP claimed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO claimed
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed